Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 101–200 of 1,000
Chaft, J. E., Oezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01962-5 · Cited by 247
“Small studies of neoadjuvant nivolumab mono-therapy have demonstrated MPR rates of 22–45% 2,3 .”
BackgroundSelf-citationElkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Couey, M. A., Bell, R. B., Patel, A. A., Romba, M. C., Crittenden, M. R., Curti, B. D., Urba, W. J., & Leidner, R. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0645-6 · Cited by 243
Ferris, R. L., Spanos, W. C., Leidner, R., Gonçalves, A., Martens, U. M., Kyi, C., Sharfman, W., Chung, C. H., Devriese, L. A., Gauthier, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002568 · Cited by 228
Self-citationMarron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00385-x · Cited by 239
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Mino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F. R., Jain, D., Lopez-Rios, F., Tsao, M. S., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 226
“Published studies in chemotherapy and chemoradiotherapy revealed prognostic significance of MPR with a cutoff of 10% or less viable tumor.138,139,150,151 More recent studies suggested the best cutoff of 10% viable tumor for squamous cell carcinoma and that of 65% for adenocarcinoma.140,152,153 Preliminary data suggest…”
BackgroundImmune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26974-6 · Cited by 218
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
Wang, S., Sun, J., Chen, K., Ma, P., Lei, Q., Xing, S., Cao, Z., Sun, S., Yu, Z., Liu, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02006-4 · Cited by 222
“Previous studies showed that tumor-specific T cells can only be found in the peripheral blood at a minimal level post treatment with PD-1 antibodies, but barely detected before the treatment [14, 15].”
BackgroundThe role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221
Cascone, T., Leung, C. H., Weissferdt, A., Pataer, A., Carter, B. W., Godoy, M. C. B., Feldman, H., William, W. N., Xi, Y., Basu, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02189-0 · Cited by 215
Self-citationAmaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30332-8 · Cited by 218
Self-citationAdvancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer
Chaft, J. E., Shyr, Y., Sepesi, B., & Forde, P. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01589 · Cited by 210
Self-citationWise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3351 · Cited by 197
Chen, J., Tan, Y., Sun, F., Hou, L., Zhang, C., Ge, T., Yu, H., Wu, C., Zhu, Y., Duan, L., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-02064-6 · Cited by 216
“Discussion Immune checkpoint inhibitor has achieved significant success in treating melanoma and blood cancers, but its efficacy on solid cancer types remains relatively low [3, 30].”
Zhang, Y., Song, J., Zhao, Z., Yang, M., Chen, M., Liu, C., Ji, J., & Zhu, D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.016 · Cited by 210
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 207
“Among these 185 arms, the agents administrated were nivolumab (n = 68, 6403 patients), pembrolizumab (67, 8124), atezolizumab (22, 4094), avelumab (17, 1785), durvalumab (9, 1674), and cemiplimab (2, 85).”
BackgroundRevisiting neoadjuvant therapy in non-small-cell lung cancer
Saw, S. P. L., Ong, B.-H., Chua, K. L. M., Takano, A., & Tan, D. S. W. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00383-1 · Cited by 198
Mountzios, G., Remon, J., Hendriks, L. E. L., García-Campelo, R., Rolfo, C., Van Schil, P., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 199
Self-citationEvolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang, S., Liu, Y., Zheng, H., Zhang, L., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000492 · Cited by 189
“Nine of the 20 resected tumors showed a complete pathological response (45%)([14]).”
BackgroundInfluentialNeoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
Uprety, D., Mandrekar, S. J., Wigle, D., Roden, A. C., & Adjei, A. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.020 · Cited by 201
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02660-6 · Cited by 198
Self-citationLeidner, R., Crittenden, M., Young, K., Xiao, H., Wu, Y., Couey, M. A., Patel, A. A., Cheng, A. C., Watters, A. L., Bifulco, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002485 · Cited by 190
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
“The future of CPIs therefore knows no limits in NSCLC at present, with recent data suggesting it may eventually be employed in the neoadjuvant setting – a question which a number of phase III trials are now pursuing further [49].”
BackgroundAnagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 200
Self-citationThe impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y.-N., Lee, H.-H., Hsu, J. L., Yu, D., & Hung, M.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 192
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 191
Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 192
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Suresh, K., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J., de Flores, M. V., Cappelli, L., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 192
Self-citationBakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0398-7 · Cited by 192
“In addition, rapid expansion of mutationassociated, neoantigen-specific T-cells was observed as early as 2 to 4 weeks following initial nivolumab administration demonstrating the additional benefit of neoadjuvant treatment [66].”
BackgroundCurrent Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 184
“In evaluating the resection specimens in a cohort of 20 patients treated with neoadjuvant nivolumab, the two extremes of the group were compared — nine patients with 10% or less residual viable tumor, and four with more than 90% residual tumor volume.(34) The pathologic features of the regression bed included prolifer…”
BackgroundMethodInfluentialSelf-citationThe Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
“In the first, two doses of nivolumab (3 mg/kg) were administered every 2 weeks, with surgery at week 4 resulted in pCR of 45% (73% RFS at 18 months; ref.”
BackgroundInfluentialHaragan, A., Field, J. K., Davies, M. P. A., Escriu, C., Gruver, A., & Gosney, J. R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.005 · Cited by 179
Intratumoral Immunotherapy for Early-stage Solid Tumors
Hong, W. X., Haebe, S., Lee, A. S., Westphalen, C. B., Norton, J. A., Jiang, W., & Levy, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3642 · Cited by 183
“Finally, neoadjuvant immunotherapy capitalizes on the presence of primary tumor as a rich source of antigens for T-cell priming (14, 15).”
BackgroundPan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2379 · Cited by 177
“MCC Nivolumab NCT02488759 (36) NSCLC Nivolumab NCT02259621 (15, 18)”
BackgroundInfluentialSelf-citationSpicer, J. D., Cascone, T., Wynes, M. W., Ahn, M.-J., Dacic, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.010 · Cited by 161
Self-citationUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Haanen, J., Ernstoff, M., Wang, Y., Menzies, A., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J., & Obeid, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000604 · Cited by 167
Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq
Song, Q., Hawkins, G. A., Wudel, L., Chou, P., Forbes, E., Pullikuth, A. K., Liu, L., Jin, G., Craddock, L., Topaloglu, U., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2113 · Cited by 168
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
“In tumors with MPR after PD-1 blockade, new infiltration with PD-1–positive CD8þ T cells was reported, a finding that was consistent with an adaptive PD-L1 up-regulation mechanism.(158) Neoadjuvant ICI studies reported MPR ranging from”
BackgroundMethodResultInfluentialSelf-citationPadinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 159
Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0129 · Cited by 168
“These 3 clonotypes were also identified as being specific for MANA #7 in an assay of T cells obtained from this patient 44 days after surgical resection (16).”
BackgroundMethodSelf-citationNeoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001282 · Cited by 165
Self-citationChoucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
“, assessed the effect of TMB in patients with stage I, II, or IIIA resectable NSCLC (n= 22) treated with neo-adjuvant nivolumab therapy [97].”
BackgroundSun, X., Liu, W., Sun, L., Mo, H., Feng, Y., Wu, X., Li, C., Chen, C., Li, J., Xin, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005531 · Cited by 181
Shu, D. H., Ho, W. J., Kagohara, L. T., Girgis, A. A., Shin, S. M., Danilova, L., Lee, J. W., Sidiropoulos, D. N., Mitchell, S., Munjal, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01992-w · Cited by 180
“Neoadjuvant immunotherapy involves the administration of ICB before surgery 1,12–15 .”
Self-citationNeoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Kang, J., Zhang, C., & Zhong, W. (2021) · Cancer Communications · doi:10.1002/cac2.12153 · Cited by 160
“[47] NCT02259621 II IB-IIIA 21 Safety, Feasibility Nivolumab: 3 mg/kg, Q2W, 2 cycles 95% 45% 15% 4.”
BackgroundInfluentialManagement of locally advanced non‐small cell lung cancer: State of the art and future directions
Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., Li, W., & Xia, Y. (2023) · 癌症:英文版 · doi:10.1002/cac2.12505 · Cited by 188
“…complete response (pCR) rate of 10% in patients with stage I-IIIA resectable disease after 2 pre-operative cycles of nivolumab; recurrence-free survival (RFS) rates at 3, 4, and 5 years were 65%, 60%, and 60%, respectively, and the corresponding OS rates were 85%, 80%, and 80% [49, 50].”
BackgroundResultInfluentialThe role of dendritic cells in cancer
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.006 · Cited by 157
Recent advances in therapeutic strategies for non-small cell lung cancer
Su, P., Furuya, N., Asrar, A., Rolfo, C. D., Li, Z., Carbone, D. P., & He, K. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01679-1 · Cited by 181
“The implementation of neoadjuvant or adjuvant immunotherapy has been shown to improve DFS among patients with early-stage NSCLC [99].”
Radiotherapy and immunotherapy: open questions and future strategies
Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 173
Ferroptosis: a double-edged sword mediating immune tolerance of cancer
Dang, Q., Sun, Z., Wang, Y., Wang, L., Liu, Z., & Han, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05384-6 · Cited by 164
“Although immunotherapy with ICIs has generated significant positive applications in a subset of cancer patients, there are still numerous mechanisms of tumors to motivate drug resistance.”
BackgroundInfluentialYin, Z., Yu, M., Ma, T., Zhang, C., Huang, S., Karimzadeh, M. R., Momtazi‐Borojeni, A. A., & Chen, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001698 · Cited by 162
Colorectal cancer immunotherapy-Recent progress and future directions
Zhao, W., Jin, L., Chen, P., Li, D., Gao, W., & Dong, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215816 · Cited by 164
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Zhang, L., Mai, W., Jiang, W., & Geng, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594558 · Cited by 167
Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150
Self-citationZhang, J., Ji, Z., Caushi, J. X., El Asmar, M., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2931 · Cited by 152
“We recently detected peripheral expansion of neoantigenspecific peripheral T-cell clonotypes that were also observed in high abundance in the posttreatment tumor in a single patient with MPR (3).”
BackgroundMethodInfluentialSelf-citationWang, D., Niu, X., Wang, Z., Song, C.-L., Huang, Z., Chen, K.-N., Duan, J., Bai, H., Xu, J., Zhao, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1086 · Cited by 150
Advances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 168
“94 Meanwhile, in addition to effector T cells, TPEX cells have also been observed to increase in the peripheral blood of NSCLC patients responding to anti-PD-1 therapy.”
BackgroundPalakurthi, S., Kuraguchi, M., Zacharek, S. J., Zudaire, E., Huang, W., Bonal, D. M., Liu, J., Dhaneshwar, A., DePeaux, K., Gowaski, M. R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0595 · Cited by 147
“Our observation that groups treated with anti–PD-1, either as monotherapy or in combination with erdafitinib, had increased numbers of tumor-specific clones that were expanded in the periphery is consistent with results in the clinic, where tumors that exhibited a pathologic response to neoadjuvant anti–PD-1 treatment…”
ResultDuhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 156
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
“Tumor mutation burden is regarded as a surrogate of neoantigen burden which heralds the therapeutic response after ICI treatment [78].”
BackgroundResultThe intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 141
“A recent pilot study in early stage NSCLC showed that neoadjuvant nivolumab induced a pathological response in 45% of resected tumors without significant adverse events or a delay in the surgical procedure.(4) Different from standard”
BackgroundAn update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 161
Versluis, J. M., Menzies, A. M., Sikorska, K., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Eriksson, H., Klop, W. M. C., Ch’ng, S., van Thienen, J. V., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.004 · Cited by 151
Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazières, J., Oliveira, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0436 · Cited by 161
Self-citationKim, W., Chu, T. H., Nienhüser, H., Jiang, Z., Portillo, A. D., Remotti, H. E., White, R. A., Hayakawa, Y., Tomita, H., Fox, J. G., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.036 · Cited by 155
Ju, W., Xia, R., Zhu, D., Dou, S., Zhu, G., Dong, M., Wang, L., Sun, Q., Zhao, T., Zhou, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33080-8 · Cited by 153
Cao, D., Xu, H., Xu, X., Guo, T., & Ge, W. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629258 · Cited by 155
“Previous studies have revealed several promising biomarkers for predicting the efficacy of ICIs, such as immune-related adverse events (irAEs),(50) PD-1/L-1 expression,(51) neutrophillymphocyte ratio (NLR),(52) mismatch repair deficiency (MRD),(53) and tumor-infiltrating lymphocytes (TIL).(19) Most of these markers ha…”
BackgroundLocalization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 152
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari, D., Battistello, E., Dheilly, E., Petruzzella, A. S., Mina, M., Sordet‐Dessimoz, J., Peters, S., Krueger, T., Gfeller, D., Riggi, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1274 · Cited by 153
“Furthermore, immune-checkpoint inhibitors (ICI) in the neoadjuvant setting are currently of great interest in non–small cell lung cancer, as shown by recent results with the PD-1 inhibitor nivolumab, which led to major pathologic response in 45% of the patients (64).”
Determinants for Neoantigen Identification
Garcia-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 137
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Baruch, E. N., Gleber‐Netto, F. O., Nagarajan, P., Rao, X., Akhter, S., Eichwald, T., Xie, T., Balood, M., Adewale, A., Na’ara, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09370-8 · Cited by 156
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 141
Kelly, R. J., Landon, B. V., Zaidi, A. H., Singh, D., Canzoniero, J. V., Balan, A., Hales, R. K., Voong, K. R., Battafarano, R. J., Jobe, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02877-z · Cited by 147
“Neoantigen-specific T cells were detected in peripheral blood using the Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) assay as described previously 17,18 , with minor modifications (Supplementary Tables 12–18).”
BackgroundMethodInfluentialSelf-citationQualifying antibodies for image-based immune profiling and multiplexed tissue imaging
Du, Z., Lin, J.-R., Rashid, R., Maliga, Z., Wang, S., Aster, J. C., Izar, B., Sorger, P. K., & Santagata, S. (2019) · Nature Protocols · doi:10.1038/s41596-019-0206-y · Cited by 134
The current knowledge concerning solid cancer and therapy
Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22900 · Cited by 143
Verschoor, Y. L., van de Haar, J., van den Berg, J. G., van Sandick, J. W., Kodach, L. L., van Dieren, J. M., Balduzzi, S., Grootscholten, C., Ijsselsteijn, M. E., Veenhof, A. A. F. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02758-x · Cited by 158
Current status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J., Wauters, E., Reymen, B. J. T., Ackermann, C. J., Peters, S., & Ruysscher, D. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz175 · Cited by 145
Sun, Y., Wu, P., Zhang, Z., Wang, Z., Zhou, K., Song, M., Ji, Y., Zang, F., Lou, L., Rao, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.010 · Cited by 139
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 143
Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population
Zidar, D. A., Al-Kindi, S. G., Liu, Y., Krieger, N. I., Perzynski, A. T., Osnard, M., Nmai, C., Anthony, D. D., Lederman, M. M., Freeman, M. L., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16526 · Cited by 136
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Yi, M., Li, A., Zhou, L., Chu, Q., Luo, S., & Wu, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02817-z · Cited by 149
“In the clinic, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) exhibit a potent and durable anti-tumor activity in LUAD patients [10].”
BackgroundHellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P. S., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3418 · Cited by 125
“In patients with long-term benefit to PD-(L)1 blockade, it is challenging to determine whether there is active residual disease and/or when it might be appropriate to discontinue treatment, especially in the context of emerging evidence for late immunologic sequelae that can have ambiguous radiographic correlates (2,…”
BackgroundSelf-citationRoch, B., Coffy, A., Jean-Baptiste, S., Palaysi, E., Daurès, J., Pujol, J.-L., & Bommart, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.003 · Cited by 137
Reardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 136
Self-citationPD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes
Nagasaki, J., Inozume, T., Sax, N., Ariyasu, R., Ishikawa, M., Yamashita, K., Kawazu, M., Ueno, T., Irie, T., Tanji, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110331 · Cited by 134
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 131
“This effect was further intensified by additional blockade of PD-1, whereby T cell activation in the lymph nodes promoted CD8+ T cell infiltration as well as neoantigen-specific T cell clonal expansion in peripheral blood and subsequent infiltration of TILs into tumor beds (251).”
BackgroundThe clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations
Villani, A., Davidson, S., Kanwar, N., Lo, W. W., Li, Y., Cohen‐Gogo, S., Fuligni, F., Edward, L.-M., Light, N. D., Layeghifard, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00474-y · Cited by 138
“The results of clinical testing are indicated by the superscript numbers: (1) negative for EWS-FLI1, CIC-DUX4 and SSX-SYT fusion transcripts; (2) negative for SYT and EWS gene rearrangements; (3) no malignant cells; (4) positive for EWSR1 gene rearrangement; (5) negative for EWS-WT1 (RT–PCR) and negative Nanostring as…”
Heymach, J. V., Mitsudomi, T., Harpole, D. H., Aperghis, M., Jones, S., Mann, H., Fouad, T. M., & Reck, M. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.010 · Cited by 136
Wislez, M., Mazières, J., Lavolé, A., Zalcman, G., Carre, O., Egenod, T., Caliandro, R., Dubos‐Arvis, C., Jeannin, G., Molinier, O., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005636 · Cited by 130
Wu, D., Li, Y., Xu, P., Fang, Q., Cao, F., Lin, H., Li, Y., Su, Y., Lu, L., Chen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46444-z · Cited by 139
“Neoadjuvant therapy with immune checkpoint inhibitors has been demonstrated to be promising in various types of cancer,such as melanoma 12,13 , non-small cell lung cancer 14 , and bladder cancer 15 .”
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Li, Z., Song, W., Rubinstein, M., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 119
“the pathological response to PD-1 blockade, and the treatment induced expansion of neoantigen-specific T-cell clones in peripheral blood [94].”
BackgroundFranken, A., Bila, M., Mechels, A., Kint, S., Dessel, J. V., Pomella, V., Vanuytven, S., Philips, G., Bricard, O., Xiong, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.007 · Cited by 135
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.